Short Interest in Innate Pharma S.A. (NASDAQ:IPHA) Decreases By 13.7%

Innate Pharma S.A. (NASDAQ:IPHA) saw a significant drop in short interest in March. As of March 31st, there was short interest totalling 76,900 shares, a drop of 13.7% from the March 15th total of 89,100 shares. Based on an average daily volume of 10,000 shares, the days-to-cover ratio is currently 7.7 days.

Institutional Trading of Innate Pharma

Hedge funds have recently bought and sold shares of the business. BlackRock Inc. increased its position in Innate Pharma by 27.4% in the first quarter. BlackRock Inc. now owns 504,408 shares of the company’s stock worth $1,695,000 after buying an additional 108,335 shares during the last quarter. Optiver Holding B.V. grew its position in shares of Innate Pharma by 132.6% in the third quarter. Optiver Holding B.V. now owns 190,219 shares of the company’s stock valued at $481,000 after purchasing an additional 108,423 shares in the last quarter. Millennium Management LLC grew its position in shares of Innate Pharma by 389.8% in the fourth quarter. Millennium Management LLC now owns 71,684 shares of the company’s stock valued at $267,000 after purchasing an additional 57,050 shares in the last quarter. Exchange Traded Concepts LLC grew its position in shares of Innate Pharma by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 46,888 shares of the company’s stock valued at $131,000 after purchasing an additional 11,890 shares in the last quarter. Finally, Jane Street Group LLC grew its position in shares of Innate Pharma by 156.3% in the first quarter. Jane Street Group LLC now owns 37,736 shares of the company’s stock valued at $127,000 after purchasing an additional 23,012 shares in the last quarter. 0.16% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $11.50 price target on shares of Innate Pharma in a report on Thursday, April 11th.

Innate Pharma Price Performance

Shares of Innate Pharma stock opened at $2.42 on Tuesday. The business’s fifty day simple moving average is $2.55 and its 200 day simple moving average is $2.55. Innate Pharma has a 12 month low of $1.81 and a 12 month high of $3.57. The company has a current ratio of 3.73, a quick ratio of 3.73 and a debt-to-equity ratio of 0.60.

Innate Pharma Company Profile

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), an Anti-C5aR Antibody; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.